Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Saniona ABLTS:0RQJ -0.17%52 Earnings per Share (Diluted) is kr1.30 as of Jun. 2026. GuruFocus rates LTS:0RQJ with a GF Score™ of 52/100 and a GF Value™ of kr25.71 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Saniona AB ranks worse than 86206.81% on this metric.
Saniona AB's EPS (Basic) for the
three
months ended in Jun. 2026 was kr-0.42.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr1.34.
Saniona AB's EPS without NRI for the
three
months ended in Jun. 2026 was kr-0.42.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr1.30.
During the past 13 years, Saniona AB's highest 3-Year average EPS without NRI Growth Rate was 26.80% per year. The lowest was -121.30% per year. And the median was -16.85% per year.
Saniona AB (LTS:0RQJ) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Saniona AB Earnings per Share (Diluted) Related Terms
Saniona AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Saniona AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RQJ vs VRTX, REGN, MRNA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, Saniona AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Saniona AB's PE Ratio falls into.
Saniona AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Saniona AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr1.30 mean?
Saniona AB (LTS:0RQJ) has a Earnings per Share (Diluted) of kr1.30 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #999999 out of 1160 companies in the Biotechnology industry.
Is Saniona AB's Earnings per Share (Diluted) too high?
Saniona AB's current Earnings per Share (Diluted) is kr1.30. Based on the distribution chart, Saniona AB ranks #999999 out of 1160 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Saniona AB has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's Earnings per Share (Diluted) compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #999999 out of 1160 companies for Earnings per Share (Diluted). This places Saniona AB in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Saniona AB and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current Earnings per Share (Diluted) is kr1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (LTS:0RQJ) is currently considered Significantly Undervalued. The stock's GF Value™ is kr25.71, compared to a current price of kr11.83 — trading 54% below its estimated fair value. The current Earnings per Share (Diluted) is kr1.30. Saniona AB's overall GF Score™ is 52/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Saniona AB (LTS:0RQJ), the current Earnings per Share (Diluted) is kr1.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (LTS:0RQJ) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr11.83 is trading 54% below its estimated GF Value™ of kr25.71.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for LTS:0RQJ:
Earnings per Share (Diluted): kr1.30
GF Value™: kr25.71 vs. price of kr11.83 (54% below fair value)
No single metric tells the full story. See the LTS:0RQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
52GF Score
Get the complete analysis for LTS:0RQJ
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RQJ has been successfully added to your 
